Target Corporation arrives at its May 20 Q1 earnings with an unusual setup: short sellers are unwinding positions at a steady clip even as options traders add a thin layer of caution. The stock has recovered 7% over the past month to $128.82, and the Street is quietly revising targets higher — yet the consensus mean of $126 still trails the current price by a whisker.
The short-selling story has shifted notably over the past few weeks. Short interest peaked above 19 million shares in mid-April and has fallen roughly 15% since then, landing at 3.56% of the free float — a moderate level that removes most of the drama. The ORTEX short score has eased alongside it, dropping from around 37 in late April to 34.8 today, reflecting a less aggressive short-side posture. Borrowing remains essentially free at 0.46% annualised, even after a 25% week-on-week spike — in absolute terms, that's still noise. Availability is extremely loose, with lending-pool supply far exceeding demand, so there is no meaningful squeeze dynamic at play. The retreat in short interest looks like profit-taking after April's tariff-driven positioning rather than any structural change.
Options traders are slightly more guarded than usual. The put/call ratio has drifted up to 0.83, about 1.5 standard deviations above its 20-day average of 0.79, suggesting incrementally heavier demand for downside protection ahead of the print. But the reading is well below the 52-week high of 0.98, and the RSI sits at a neutral 58.6. This is a mildly cautious market, not a frightened one. Closest peer was up 1% on the week while fell 4.6% — the discount-retail group remains volatile around macro headlines, but Target's own tape has been steadier.
The Street's view is gradually improving, though outright bullishness is still scarce. Citigroup's Paul Lejuez lifted his target to $133 from $117 this week — the only move in the past 14 days — while keeping a Neutral rating. Evercore ISI and Guggenheim both raised targets in late April, the latter to $140. BNP Paribas is the outlier with an Underperform and an $88 target. With the mean sitting at $126, just below Tuesday's close, the aggregate analyst community is roughly flat on return potential at -2.2% — a setup that leaves little room for valuation re-rating without an earnings beat. The P/E has expanded about 5% over the past month to around 15.8x, which is undemanding for a large-cap retailer but reflects a business facing genuine volume pressure from tariff uncertainty and a promotional environment. The 12-month forward yield is 3.6% — the dividend score ranks in the 98th percentile of the universe, a meaningful floor for income-oriented holders.
On the ownership side, BlackRock added 2.5 million shares in the most recent reported quarter to reach a 7.65% stake, while Vanguard and State Street both trimmed modestly. FMR added nearly 1.7 million shares. The net of those flows is constructive at the margin, but the positions are large passive weights rather than conviction active bets. Insider activity in early April was routine — award grants followed by same-day tax-withholding sales across several officers including CFO Michael Fiddelke ($620k) and CEO Brian Cornell ($2.6m). Both sales were paired with awards and carry no directional signal.
The reaction at the last two earnings prints is worth noting. In March, the stock jumped 6.1% in the session and held most of those gains over the following week. In November, it fell 5.5% on the day before recovering into a modest one-week gain. The results have been binary and post-print fades have been limited — a pattern that makes the PCR drift upward before May 20 worth watching as the print approaches.
See the live data behind this article on ORTEX.
Open TGT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
